Global Paediatric Epilepsy Therapeutics Market – Industry Trends and Forecast to 2030

Paediatric Epilepsy Therapeutics Market Analysis and Size

The occurrence of epileptic seizures is more in low to middle-income countries, which drives the demand for epileptic seizure treatment is highly developed countries. According to the Epilepsy Foundation, only about 25 % of people who have Status Epilepticus will have epilepsy. Also, in many cases, it happens to children under the age of 15 years and adults above 40 years. There are numerous complications of epilepsy that can range from no complications to death.

Data Bridge Market Research analyses a growth rate in the paediatric epilepsy therapeutics market in the forecast period 2023-2030. The expected CAGR of paediatric epilepsy therapeutics market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 11.45 billion in 2022, and it would grow up to USD 16.91 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Paediatric Epilepsy Therapeutics Market Scope and Segmentation

Market Definition

Epilepsy is typically zed as a chronic neurological disorder that can cause recurrent unprovoked seizures followed by undetectable episodes of involuntary movement.  The major causes can be infections, genetic mutations, brain injury and a tumour that leads to abnormal blood vessels development and bleeding in the kids' brain. The children suffering from autism, down syndrome, and other metabolic disorders may possibly to have epilepsy. Symptoms include uncontrollable jerking movements, temporary confusion, fear, anxiety and others.

Paediatric Epilepsy Therapeutics Market Dynamics

Drivers

• Growing Incidence of Neurological Disorders

Increased occurrence of epilepsy and rising incidence of neurological disorder are expected to increase the demand for paediatric epilepsy therapeutics, which is projected to boost the market growth during the forecast period. For instance, in June 2019, as per the World Health Organization (WHO), epilepsy affects more than 50 million individuals globally. Furthermore, seizure recurrence is caused by abnormal brain activity. This boosts the market growth.

• Increasing Number of Drug Developments

Emerging potential drugs in pipeline is projected to drive the market during the forecast period. For instance, in October 2020, Marinus Pharmaceuticals started randomized clinical trial for drug Ganaxolone. This study assessed the effectiveness and safety of IV ganaxolone, for the treatment of patients suffering from epilepsy.

Opportunities

• Increase in Head Injuries and Brain Cancer

As per the NCBI, brain tumors are the second most common cause of epilepsy in the elderly population, resulting for 10% to 30% of all causes of geriatric epilepsy. Seizures are the onset symptom in 20% to 40% of brain tumor patients; around 20% to 45% of patients are possibly to have epileptic seizures in the course of the disease. As per the International League Against Epilepsy (ILAE), infections in the central nervous system, such as meningitis, encephalitis, and neurocysticercosis, can lead to both acute symptomatic seizures and epilepsy.

• Increased Government Initiatives and Funding

There have been growing funding between numeorus organizations that can cause market growth. For instance, in March 2021, American Epilepsy Society granted fund for prolonged epilepsy up to US$ 50,000 and are projected to support the establishment of national or global multicenter research initiatives. Each award will provide funding for organisational planning sessions, infrastructure development, or pilot studies, which allows the research programme to compete for future investment.

Restraints/Challenges

• High Cost of Treatment

The augmented expenditure that is required for the multiple treatment processes restrict the market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.

This paediatric epilepsy therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the paediatric epilepsy therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2022, UCB announced plans to acquire Zogenix for US$ 1.9 Bn to add Fintepla (Fenfluramine), a marketed drug for treating seizures related to the Dravet syndrome. The transaction adds a newly marketed product for patients with rare and difficult-to-treat pediatric orphan epilepsy syndromes to UCB's extensive therapeutic offerings in the epilepsy market.
• In 2021, Dr. Reddy's Laboratories announced the antiepileptic medication Vigabatrin tablets in the U.S. market after receiving approval from the US FDA.

Global Paediatric Epilepsy Therapeutics Market Scope

The paediatric epilepsy therapeutics market is segmented on the basis of diseases type, therapeutics, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diseases Type

• Benign Rolandic Epilepsy
• Infantile Spasms
• Lennox-Gastaut Syndrome
• Others

Therapeutics

• Surgical Therapies
• Dietary Supplements
• Vagal Nerve Stimulation
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Paediatric Epilepsy Therapeutics Market Regional Analysis/Insights

The paediatric epilepsy therapeutics market is analyzed and market size insights and trends are provided by disease type, therapeutics, distribution channel and end-user as referenced above.

The major countries covered in the paediatric epilepsy therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market because of the occurrence of key manufacturers of the product is high and, increasing research and development activities.

Asia-Pacific is considered to grow over the upcoming years because of augmented new research and developments on paediatric epilepsy therapeutics market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Paediatric Epilepsy Therapeutics Market  Share Analysis

The paediatric epilepsy therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to paediatric epilepsy therapeutics market

Key players operating in the paediatric epilepsy therapeutics market include:

• GSK Plc. (U.K.)
• Pfizer Inc. (U.S.)
• Medtronic (Ireland)
• UCB S.A. (Belgium)
• NeuroPace, Inc (U.S.)
• Jazz Pharmaceuticals, Inc (U.K.)
• Novartis AG (Switzerland)
• Johnson & Johnson Services, Inc. (India)
• Abbott (U.S.)
• Sage Therapeutics, Inc (U.S.)
• Sunovion Pharmaceuticals Inc (U.S.)
• Sanofi (France)
• Bausch Health Companies Inc. (Canada)
• Amneal Pharmaceuticals LLC (U.S.)

SKU-57393